Abstract: Malaria, known as the "fevers," has been treated for over three thousand years in China with extracts of plants of the genus Artemisia (including Artemisia annua, A. opiacea, and A. lancea) from which the active compound is artemisin, a sesquiterpene that is highly effective in the treatment of the disease, especially against young forms of the parasite. South American Indians in the seventeenth century already used an extract of the bark of chinchona tree, commonly named "Jesuits' powder." Its active compound was isolated in 1820 and its use spread all over the world being used as a prophylactic drug during the construction of the Madeira-Mamoré railroad in the beginning of the twentieth century. During the 1920s to the 1940s, new antimalarial drugs were synthesized to increase the arsenal against this parasite. However, the parasite has presented systematic resistence to conventional antimalarial drugs, driving researchers to fi nd new strategies to treat the disease. In the present review we discuss how Brazil treats Plasmodium-infected patients.
Introduction
Malaria is one of the worst health problems in this decade according to the World Health Organization (WHO). Globally, the disease takes the heavy toll of more than one million lives every year. Most of the victims are under the age of fi ve. These astonishing numbers show that one infant dies of malaria every 30 seconds. In the face of this dramatic situation, malaria still continues to receive insuffi cient attention, due to the fact that the disease mainly affects tropical and subtropical regions of the world rather than temperate zones where industrial and fi nancial power are concentrated. For this reason, malaria is considered a neglected disease.
Considering the pharmaceutical treatment of malaria, we encounter several diffi culties. Since the fi rst antimalarial drug synthesis, advances in the comprehension of its mode of action and in the development of new effective antimalarials have been disappointing. The need for low-cost drugs, problems of drug toxicity, and the spread of antimalairal drug resistance in the parasite combine to create a very disturbing scenario for malaria management.
Improving malaria treatment is, more than ever, an issue of great importance. Despite increasing investments in measures against the disease, this problem still needs highly skilled approaches to provide effective prevention and treatment of the disease. 1 
Antimalarials
The fi rst historical record of a compound with antimalarial properties dates back to 1638, when the physician Juan de la Vega administered quina, the bark of a tree native to tropical South America now known as cinchona, to the wife of the Viceroy of Peru, treating her illness effectively. 2 In 1820 quinine was discovered to be the active compound of quina's antimalarial properties. For a long time, quinine was the only antimalarial drug available, and its economic importance rose substantially in the 19th century. Many attempts to synthesize the compound were unsuccessful, until an effi cient synthesis method was described in 1944. Although quinine has been widely used for centuries, it has high toxicity and needs to be administered several times a day due to its short pharmacological half-life. 3 Hence, efforts were mobilized to fi nd suitable substitutes for quinine. In 1891, Guttman and Ehrlich were the fi rst to report the antimalarial properties of a synthetic compound when they observed the successful treatment of two patients, using the dye methylene blue. 4 Much later, in 1932, the synthesis of the fi rst antimalarial, pamaquine, was achieved, 5 followed by the synthesis of atebrin (quinacrine), an 8-aminoquinoline derivative, with antimalarial properties. 6 However, due to the high toxicity of these 8-aminoquinolines, new efforts were made in 1940s to fi nd alternatives, leading to the discovery and synthesis of new antimalarials. The new drugs included proguanil, the fi rst antifolate used to treat malaria, and the two 4-aminoquinolines resochin (later renamed chloroquine) and sontaquine, as well as quinine, as already mentioned. 7 Chloroquine rapidly gained popularity due to its high effi ciency, low toxicity, cheap production cost and high availability. 8 Unfortunately, improper usage in a single-drug regimen during the 1950s and 1960s led to the emergence of chloroquine-resistant parasites. 9 During the last few decades, only a small number of new antimalarials have been made available as suitable drugs to treat and control malaria effectively, although during the period 1975-1999 almost 1400 new drugs were registered worldwide. 10 This new generation included the 4-quinoline-methanol, mefl oquine, 11 the 9-phenanthrenemethanol, halofantrine, 12 the 8-aminoquinoline, primaquine, the 2-hydroxinaphthoquinone, atovaquone (discovered in the early 1940s, but only licensed in 1997), 13 the artemisin-based compounds such as artesunate and the antifolates such as sulfadoxine and pyrimethamine.
Most of the antimalarials available nowadays fall into three classes: the quinolines, the artemesin-based antimalarials, and the antifolates. However, drug resistance to these compounds is spreading rapidly and we face a situation where, in some cases, almost no completely effective drug can be found to treat malaria. 14 The discovery and development of new effective antimalarial drugs are now issues of great importance. Rather than focusing investment in the traditional mass-screening of chemicals for antimalarial action, the aim needs to turn to increase the understanding of how available antimalarials 
Drug Dosage
Artesunate 600 mg plus Mefl oquine 250 mg 1 tablet daily for 3 days 6 tablets 1 unique dose (1,5 g) work at the molecular level in order to provide a sound rationale for the design of new and better drugs.
Antimalarial action
For the most exploited group of antimalarials, the quinolines, little is known about how precisely they work, although there are many hypotheses. The fi rst fact that needs to be highlighted is that some quinolines, particularly chloroquine, tend to accumulate in the parasite's digestive vacuole (food vacuole), suggesting that this acidic compartment might be their main site of action. An interesting model has been proposed to explain this unusual accumulation, based on the known behavior of such weak diprotic bases. It is possible that, after entering the parasite, these quinolines become trapped inside the digestive vacuole where in its acid environment they gain an extra proton to add to their original monoprotonated state. With this additional proton, the quinolines are unable to pass back through the enclosing membrane of the digestive vacuole. The observed accumulation of quinolines in the digestive vacuole prompted further work on their mode of action, which led to the discovery of another very peculiar effect, their inhibition of the synthesis of the hemozoin pigment by the parasite. 15 This pigment is formed in the digestive vacuole as a result of the parasite's feeding on the hemoglobin within the red blood cell it inhabits.
The digestion of hemoglobin is catalyzed in the digestive vacuole by several proteolytic enzymes including plasmepsins I, II, and IV, histoaspartic protease (HAP), falcipain 2, falcipain 3, and falcilysin. 15 Beside the aminoacids generated from the degradation of the protein component of hemoglobin, toxic intermediates derived from the heme group are also produced, but these are rapidly converted by the parasite into the nontoxic crystalline brown pigment, hemozoin. This detoxifi cation process entails fi rst the oxidation of the heme product ferrous protoporphyrin IX, into ferric protoporphyrin IX, also called hematin.
Ferric protoporphyrin IX then aggregates by a nonenzymatic process into crystals of hemozoin. The process of crystallization is not fully understood and may require parasite-derived molecules to initiate. It is hypothetized that quinolines inhibit this process, causing a toxic accumulation which is fatal to the parasite. However, some data suggest that a strong inhibition of hemozoin synthesis is not necessarily correlated with a higher antimalarial activity, which weakens the hemozoin inhibition hypothesis. Another interesting effect caused by quinolines, in particular by chloroquine, is the mobilization of Ca 2+ from compartments within the parasite. 16, 17 Since this second messenger is exploited by the parasite to modulate its own life cycle and several other cellular functions, [18] [19] [20] [21] it would not be surprising that a disruption in Plasmodium Ca Notes: Quinine and doxicycline should be administered twice a day, each 12 hours, doxiciclyne and primaquine should not be administered to pregnant women, and primaquine is administered in order to eliminate P. falciparum gametocytes. homeostasis leads eventually to parasite death. Several studies on Plasmodium Ca 2+ signaling and homeostasis have been published, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] showing the crucial role of this ion in the parasite life cycle.
The remaining class of antimalarials, the artemisinrelated compounds, are thought to act by cleaving peroxide bridges, thus generating toxic free radicals. This cleaving could be related to the high effi ciency of artemisinin action, and the food vacuole is a possible target. 28 In the past twenty years, the Brazilian Ministry of Health, together with the Fundação Nacional da Saúde (National Health Foundation) aided by a committee of specialists, has periodically updated malaria therapeutics in the country, taking into consideration personal experiences or experiences based on evidence that is more suitable to Brazilian reality. 29, 30 Generally speaking, the traditional antimalarial chemical entities remain as the main drugs (Table 1) with the association of two drugs, generally differing in their capacity/speed of cleaning of blood-stage parasites in order to avoid the appearing of drug-resistant falciparum malaria. The classical association of chloroquine and primaquine was maintained for malaria vivax treatment, with some alterations or recommendations regarding the dosage. 29, 30 In 2007 and 2008, the Ministry of Health introduced new associations: artemisine and lumefantrine (Coartem ® ) ( Table 2) and artesunate with mefl oquine (Artequin ® ) ( Table 3) . When the patient is able to swallow and the parasite load is declining, oral quinine sulfate should be used, with the same dosage, each 8 hours. The treatment should be maintained until 48 hours after a negative result of the thick smear (generally 7 days) Scheme indicated to pregnant women Notes: Artemisin derivates have proven to be very effective and rapidly reduce or eliminate parasites. Therefore, it is necessary that these medications are protected from their abusive use and indicated only for serious and complicated cases. The preferential specifi c therapeutic scheme for pregnant women is the association of quinine and intravenous clindamycin due to its effectiveness and because it causes no harm either to the mother or to the child. According to handbooks, therapeutic schemes may be divided according to parasite specimen and case seriousness with special attention to special categories such as children or special situations such as allergies, intolerance, or contraindication. 29, 30 For small children, smash the tablet to make the administration easier, and have them swallow it with water or milk. It is recommended that children take the tablet with food. Do not administer the drug to pregnant women in their fi rst trimester of pregnancy nor to children less then six months of age.
P. falciparum malaria
Among the four forms of malaria, the disease caused by P. falciparum brings is the one that brings more concern to physicians, due to its high pathogenicity and resistance to drugs.
9,10-14 Nowadays, in the Amazonian rural areas, the combination of quinine and antibiotics is still widely used (Table 4) , although the tertiary and secondary centers of reference (large hospitals in specialized centers), generally choose to use Coartem ® . However, in areas outside the Amazonian region, the use of the classical association quinine and tetracycline derivates is preconized, especially doxicycline and the use of clindamycin (when there is restriction to the use of doxicycline) ( Table 5 ). We should emphasize that the use of artemisinin derivates of parenteral formulation is restricted to the serious malaria cases according to the Ministry of Health guidelines 29, 30 (Table 6 ), and that alternative rectal administration is also of value when the use of oral treatment or parenteral administration is impossible (Table 7) . Although the use of mefl oquin in the treatment of P. falciparum malaria does not present signs of signifi cant resistance in Brazil, 31 its use in monotherapy or associated to primaquine has been prohibited in the endemic areas by the present committee.
It is worth remembering that the association with only one dose of primaquine should be present when using quinine monotherapy or in combination to destroy the sexual forms.
As presented above, the character of malaria treatment in Brazil varies, according to the studied area. In some areas the use of quinine in monotherapy in pregnant women is still used in a seven day scheme (Table 8) .
P. vivax malaria
Vivax malaria, less virulent than P. falciparum malaria, is the most common form of the disease in Brazil. 29, 30 Although the classical association of chloroquine with primaquine (Table 9) for vivax malaria treatment has not changed in the past 20 years, chloroquine infusions were abolished due to operational problems. Therefore, in some cases intravenous medications for P. falciparum malaria are applied to treat vivax malaria. Nowadays, there is a tendency to maintain 1.5 g of chloroquine and adequate primaquine doses for patients weighing more than 70 kg. In case of malaria recurrence, a 50% to 100% increase in the initial dose of primaquine is recommended. In cases in which primaquine cannot be used (pregnant women, children less than six months old, persons who are defi cient in glucose 6-phosphate dehydrogenase enzyme, allergic persons, etc.), exclusive chloroquine therapy may be given 29, 30 as mentioned in Table 10 .
Malaria caused by other plasmodium species
Treatment of malaria caused by P. ovale is performed with the same protocols used for vivax malaria. Malaria caused by P. malariae, although the less frequently diagnosed in Brazil, should be treated as malaria P. vivax (Table 10) , except for the use of primaquine, since this parasite does not present hypnozoitic forms.
Conclusion
Malaria parasites have a complex life cycle. The struggle against the disease -not only in Brazil but in the whole world -is now facing a huge obstacle: the increasing appearance of parasites resistant to the classical antimalarials. Funding incentives in the area of neglected diseases have been the focus of Brazilian funding agencies, thus supporting work on several aspects such as epidemiology, system biology, immunology, and others. The multidisciplinary work is a necessity to help us to understand better this pathogen's tricks and to achieve new forms, tools, and strategies to continue the battle against this disease. Notes: This scheme is recommended to patients who suffered malaria recurrences after correct treatment and/or to pregnant women and children less than six months of age who cannot receive primaquine. Abbreviations: A, One suppository capsule should be administered each 12 hours; B, One suppository capsule should be administered each 8 hours; C, For children less than one year old and children older than 12 years, see Table 10 . Notes: 50 mg suppository capsules may be kept at room temperature. Adult and child should have 5 mg and 15 mg primaquine, respectively. Primaquine dose (0, 50 mg/kg) preferably should be taken at meals.
